Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less severe than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications and combinations by two routes of administration.

In addition to the Phase 2 clinical trial in CRC, Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials, business objectives and strategic goals, drug developme
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Smile Train and its technology partner BioDigital have been ... among leading global health innovations in The Hive at ... Washington, D.C. at The John F. Kennedy ... Train is honored to be represented through our partnership ... health and medicine that TEDMED unites each year," said ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Full ... as the new Vice President of Business Development. ... 30 years in a number of different business development ... industry. These positions were primarily related to business development/sales ... the past 30 years makes him a key and ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: ... Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... acquisition of both cultivation and dispensary medical marijuana licenses in ... the MOU, GBLX will acquire a 20% equity interest in ... GrowBLOX TM growing chambers, as well as all technology ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... 8, 2012  Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ... and commercialization of medically important pharmaceutical products for the ... results for the first quarter ended March 31, 2012. ... cash, cash equivalents, interest receivable, and investment securities of ...
... of scientists led by Dr. Stanley Fricke of the Children,s ... imaging (MRI) sound barrier," a finding that could lead to ... clinical study published this week in the peer-reviewed journal ... said Dr. Fricke, "is to image small children in seconds ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 4Children's National Medical Center Breaks MRI Speed Sound Barrier 2
(Date:7/26/2014)... Another DePuy Pinnacle hip lawsuit against Johnson ... filed by Wright & Schulte LLC. This DePuy ... an Erie County, Ohio man who alleges that he has ... since receiving his Pinnacle Hip implant in 2008. According to ... to undergo a complex and risky revision surgery to replace ...
(Date:7/26/2014)... According to the Banish My Bumps Pdf review ... that covers detailed instructions on how to eliminate ... any medication. , Vkool reveals in its review ... for relieving symptoms of keratosis pilaris quickly. In addition, ...     How to treat children's keratosis pilaris ,     How ...
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... 26, 2014 2014 Deep ... Permeation Chromatography Industry” is a professional and ... China Gel Permeation Chromatography market. The report ... Gel Permeation Chromatography definition, classification, application, and ... overview. This research covers the international market ...
(Date:7/25/2014)... According to a new market research report ... thermography, ultrasound emission, lubricating oil analysis, corrosion monitoring, ... - Global Forecast to 2014 - 2020", published ... expected to reach $2.50 at a CAGR of ... market data Tables and 57 Figures spread through ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
... The U.S. Military has selected iCRco, an American CR Company, as ... portable, fast and efficient diagnoses for our troops injured in battle. ... ... Military has selected iCRco, an American CR Company, as its new ...
... to Host Investor Conference Call on Monday, August 11, 2008 at 8:30am ... ... YORK, Aug. 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical ... for the treatment of life-threatening,diseases, including renal disease and cancer, today announced ...
... YORK, Aug. 8 Mergent, Inc., administrator ... underlying indexes for the,HealthShares Exchange Traded Funds, ... opening of trading on Monday August 11, ... Co. (Tokyo, Japan: 4518) in the,HealthShares(TM) Infectious ...
... MEDQ ) the largest Medical Transcription Service Organization,(MTSO) in ... ended June,30, 2008. Revenue for the second quarter of ... second quarter of 2007. The decrease in revenue,of $6.2 ... primarily due to,customer losses experienced during the second half ...
... Fairbanks campus will be home to the Eighth Conference ... conference is organized in cooperation with the Standing Committee ... international participants to address issues of importance to Arctic ... , More than150 guests are expected to attend at ...
... is available in French . , Montreal, ... patients who receive early treatment for Hepatitis C virus ... a rapid poly-functional immune response against HCV similar to ... study published in the Journal of Virology . ...
Cached Medicine News:Health News:US Military Chooses American Made iCRco Digital Radiography Systems 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Infectious Disease and HealthShares(TM) Composite Indexes 2Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Early treatment is key to combating hepatitis C virus 2
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Anti-Rotavirus Antigen Assay (ELISA)....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
... Acolytes core technology relates to the ... enzyme found in all living cells. ... measured using bioluminescence. By coupling ... example via extraction using antibody-coated beads, Acolyte ...
Medicine Products: